Viewing Study NCT07101159

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 2:48 PM
Ignite Modification Date: 2026-01-29 @ 12:46 AM
Study NCT ID: NCT07101159
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-08-03
First Post: 2025-07-25
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients
Sponsor: Fujian Cancer Hospital
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Early Breast Cancer View
None Adjuvant Therapy View
None Hormone Receptor Positive / HER2-negative Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None dalpiciclib View
None hormone receptor positive/HER2-negative breast cancer View
None early breast cancer View